Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
AI scribe company Suki just landed $90M in Series E funding to go beyond clinical documentation. The company plans to build AI agents that handle post-visit tasks like referrals and prior authorizations, while deepening ties with 30+ health tech partners including Optum, Zoom, and athenahealth. It's a disciplined bet in a market where rivals are raising hundreds of millions.
AI scribe company Suki has closed a $90 million Series E round, signaling its ambition to move well beyond transcribing clinical notes. The fresh capital will fund the development of AI agents capable of handling post-visit administrative tasks — think prior authorizations for new medications, referrals, and follow-up scheduling — using data already captured by Suki's existing tools.
The company also plans to go deeper with its existing network of 30+ health tech partners, rather than chasing new ones. Platforms like athenahealth's Ambient Notes and Zoom's telehealth documentation feature are already powered by Suki, and the new funding will help embed even more Suki capabilities — including the upcoming AI agents — into those partner ecosystems.
By the Numbers:
Why it matters: As AI-driven clinical tools become standard in healthcare, the race is shifting from documentation to full workflow automation. Suki's focus on post-visit administrative tasks — one of medicine's biggest time drains — could meaningfully reduce physician burden and speed up patient care pathways.
